查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954217

產前和新生兒基因檢測市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、最終用戶、流程、模式和階段

Prenatal and Newborn Genetic Testing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 385 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，產前和新生兒基因檢測市場規模將從2024年的81億美元成長至165億美元，年複合成長率約為7.5%。該市場涵蓋孕期和出生後進行的診斷和篩檢測試，旨在識別遺傳疾病和染色體異常。基因組技術的進步、父母意識的提高以及對早期診斷需求的成長是推動市場成長的主要因素。主要細分市場包括非侵入性產前檢測（NIPT）、帶因者篩檢和新生兒篩檢。隨著精準醫療的發展，該市場有望實現成長。精準醫療的特點是注重個人化醫療解決方案和提高遺傳諮詢服務的可近性。

受基因組技術進步和意識提升的推動，產前和新生兒基因檢測市場持續強勁成長。按細分市場分類，產前篩檢檢測的成長速度最快，這主要得益於非侵入性產前檢測 (NIPT) 的技術創新以及對早期發現遺傳疾病日益成長的需求。 NIPT 憑藉其高準確性和安全性，仍然是一個重要的細分市場，吸引著醫療保健提供者和準媽媽們的注意。緊隨其後的是新生兒基因檢測領域，尤其是在代謝紊亂篩檢和全基因測序，也呈現出良好的成長動能。這些細分市場之所以發展迅速，是因為它們具有早期識別罕見遺傳疾病並實現及時介入的潛力。人工智慧和機器學習在基因數據分析中的應用提高了檢測的準確性和效率，進一步推動了市場成長。隨著個人化醫療的不斷發展，對綜合基因檢測解決方案的需求預計將會增加，從而為相關人員創造盈利的機會。

市場區隔
類型 產前篩檢、新生兒篩檢、基因帶原檢測、診斷性檢測
產品 設備、試劑盒及試劑、軟體、耗材
服務 遺傳諮詢、檢測服務和數據分析
科技 次世代定序、聚合酵素鏈鎖反應、微陣列、螢光原位雜合反應
應用領域 染色體異常、遺傳性疾病、代謝性疾病
最終用戶 醫院、診斷檢查室、研究中心和專科診所
過程 檢體採集、DNA提取、定序和數據分析
實作方法 侵入性、非侵入性
步 懷孕前、生產前、分娩後

受多種新產品的推出推動，產前和新生兒基因檢測市場正經歷動態的競爭格局。提供利用先進技術的綜合檢測解決方案的公司佔據了相當大的市場佔有率。由於企業需要在價格親民和高成本之間取得平衡，定價策略的競爭日益激烈。新調查方法的引入正在重塑消費者的預期，並推動市場在各個地區的擴張。競爭基準研究揭示了市場集中度較高的格局，主要企業都在加大研發投入以維持其競爭優勢。監管的影響顯著，嚴格的指導方針影響產品開發和打入市場策略。法規環境的區域差異進一步加劇了市場的複雜性，因此需要靈活的合規策略。技術進步和人們對基因檢測益處的日益了解正在推動市場成長。這項全面的分析支持了市場的潛力，並突顯了策略投資和合作的機會。

主要趨勢和促進因素：

受技術進步和人們對遺傳疾病認知不斷提高的推動，產前和新生兒基因檢測市場正處於成長軌道上。一個關鍵趨勢是，由於其準確性和安全性，非侵入性產前檢測 (NIPT) 的普及率不斷提高。這一趨勢，加上人工智慧和巨量資料分析的整合，正在推動診斷準確性的提高和個人化醫療方案的實施。此外，政府主導和父母意識提升的增強也推動了對全面新生兒篩檢計畫的需求激增。遺傳疾病和先天性異常的盛行率不斷上升，需要早期發現和干涉，這進一步推動了市場成長。新興國家對預防性醫療保健的日益重視和醫療基礎設施的不斷改善也是市場成長的促進因素。此外，醫療服務提供者和基因檢測公司之間的合作正在推動創新並提高服務的可及性。個人化檢測套組的開發和遠距遠端醫療服務的擴展，為偏遠和醫療資源匱乏地區提供了發展機會。在不斷變化的倫理考量和法規結構下，預計該市場將繼續與全球醫療保健優先事項保持一致，並持續擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 產前篩檢
    • 新生兒篩檢
    • 基因帶原檢測
    • 診斷測試
  • 市場規模及預測：依產品分類
    • 裝置
    • 試劑盒和試劑
    • 軟體
    • 消耗品
  • 市場規模及預測：依服務分類
    • 遺傳諮詢
    • 檢查服務
    • 數據解讀
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 聚合酵素鏈鎖反應
    • 微陣列
    • 螢光原位雜合反應
  • 市場規模及預測：依應用領域分類
    • 染色體異常
    • 遺傳性疾病
    • 代謝性疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 研究中心
    • 專科診所
  • 市場規模及預測：依製程分類
    • 檢體採集
    • DNA萃取
    • 定序
    • 數據分析
  • 市場規模及預測：依實施方法分類
    • 侵入性檢查
    • 非侵入性
  • 市場規模及預測：依階段分類
    • 懷孕前
    • 產前檢查
    • 出生後

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Natera
  • Invitae
  • Myriad Genetics
  • Progenity
  • Genetic Technologies
  • Perkin Elmer
  • Veritas Genetics
  • Ariosa Diagnostics
  • Billion To One
  • Sema4
  • Color Genomics
  • Genomic Prediction
  • Fulgent Genetics
  • Good Start Genetics
  • Counsyl
  • Gene Dx
  • Cooper Genomics
  • Aperiomics
  • Juno Diagnostics
  • Predictive Laboratories

第9章：關於我們

簡介目錄
Product Code: GIS10516

Prenatal and Newborn Genetic Testing Market is anticipated to expand from $8.1 billion in 2024 to $16.5 billion by 2034, growing at a CAGR of approximately 7.5%. The Prenatal and Newborn Genetic Testing Market encompasses diagnostic and screening tests conducted during pregnancy and after birth to identify genetic disorders and chromosomal abnormalities. This market is driven by advancements in genomic technologies, rising parental awareness, and increasing demand for early diagnosis. Key segments include non-invasive prenatal testing (NIPT), carrier screening, and newborn screening. As precision medicine evolves, the market is poised for growth, emphasizing personalized healthcare solutions and expanding access to genetic counseling.

The Prenatal and Newborn Genetic Testing Market is experiencing robust expansion, fueled by advancements in genomic technologies and increasing parental awareness. Among the segments, the prenatal screening tests exhibit the highest performance, driven by innovations in non-invasive prenatal testing (NIPT) and the growing preference for early detection of genetic disorders. NIPT, with its high accuracy and safety profile, remains a critical sub-segment, attracting significant attention from healthcare providers and expectant parents alike. Following closely, the newborn genetic testing segment shows promising growth, particularly in metabolic disorder screening and whole-genome sequencing. These sub-segments are gaining momentum due to their potential to identify rare genetic conditions early, facilitating timely interventions. The integration of AI and machine learning in genetic data analysis is enhancing test accuracy and efficiency, further propelling market growth. As personalized medicine continues to evolve, the demand for comprehensive genetic testing solutions is expected to rise, presenting lucrative opportunities for industry stakeholders.

Market Segmentation
TypePrenatal Screening, Newborn Screening, Carrier Testing, Diagnostic Testing
ProductInstruments, Kits and Reagents, Software, Consumables
ServicesGenetic Counseling, Laboratory Services, Data Interpretation
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Microarray, Fluorescence In Situ Hybridization
ApplicationChromosomal Abnormalities, Genetic Disorders, Metabolic Disorders
End UserHospitals, Diagnostic Laboratories, Research Centers, Specialty Clinics
ProcessSample Collection, DNA Isolation, Sequencing, Data Analysis
ModeInvasive, Non-invasive
StagePreconception, Prenatal, Postnatal

The prenatal and newborn genetic testing market is witnessing a dynamic shift, with a diverse array of new product launches enhancing the competitive landscape. Market share is predominantly held by companies that leverage advanced technologies to offer comprehensive testing solutions. Pricing strategies are increasingly competitive, driven by the need to balance affordability with the high costs of innovation. The introduction of novel testing methodologies is reshaping consumer expectations and expanding the market's reach across various regions. Competition benchmarking reveals a concentrated market with key players investing in research and development to maintain their competitive edge. Regulatory influences are significant, with stringent guidelines shaping product development and market entry strategies. The landscape is further complicated by the varying regulatory environments across regions, necessitating agile compliance strategies. The market is poised for growth, bolstered by technological advancements and increased awareness of genetic testing benefits. This expansive analysis underscores the market's potential, highlighting opportunities for strategic investments and partnerships.

Geographical Overview:

The prenatal and newborn genetic testing market is witnessing notable growth across various regions, each with its unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and increasing awareness about genetic disorders. The presence of key players and extensive research activities further bolster this region's market position. Europe follows closely, with a strong focus on early diagnosis and preventive healthcare. Government initiatives supporting genetic testing and personalized medicine enhance the market's appeal. In Asia Pacific, the market is expanding rapidly due to rising healthcare expenditure and increasing birth rates. Emerging economies like China and India are investing significantly in healthcare technologies, creating lucrative opportunities. Latin America and the Middle East & Africa are emerging as potential growth pockets. In Latin America, improved healthcare access and rising awareness about genetic disorders are key drivers. The Middle East & Africa are recognizing the importance of genetic testing in improving maternal and child health outcomes, fostering market growth.

The Prenatal and Newborn Genetic Testing Market is navigating a complex landscape shaped by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, heightened trade tensions are prompting strategic investments in local biotechnology capabilities to mitigate dependency on foreign imports. China is accelerating its focus on self-sufficiency in genetic testing technologies amid export restrictions, while Taiwan leverages its semiconductor prowess to enhance testing equipment precision. The global market is witnessing robust growth, driven by increasing awareness and technological advancements. By 2035, the market is expected to thrive, contingent on regional collaborations and innovation. Meanwhile, ongoing Middle East conflicts exert pressure on energy prices, indirectly influencing manufacturing costs and supply chain stability across these nations.

Key Trends and Drivers:

The Prenatal and Newborn Genetic Testing Market is on a growth trajectory, propelled by technological advancements and heightened awareness of genetic disorders. Key trends include the increasing adoption of non-invasive prenatal testing (NIPT) due to its accuracy and safety. This trend is complemented by the integration of artificial intelligence and big data analytics, enhancing diagnostic precision and personalized medicine approaches. Additionally, the market is witnessing a surge in demand for comprehensive newborn screening programs, driven by government initiatives and parental awareness. Drivers of this market include the rising prevalence of genetic disorders and congenital anomalies, which necessitate early detection and intervention. The growing emphasis on preventive healthcare and the expansion of healthcare infrastructure in emerging economies further bolster market growth. Moreover, collaborations between healthcare providers and genetic testing companies are fostering innovation and accessibility. Opportunities abound in developing personalized testing kits and expanding telemedicine services, catering to remote and underserved populations. As ethical considerations and regulatory frameworks evolve, the market is poised for sustained expansion, aligning with global health priorities.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Prenatal Screening
    • 4.1.2 Newborn Screening
    • 4.1.3 Carrier Testing
    • 4.1.4 Diagnostic Testing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Kits and Reagents
    • 4.2.3 Software
    • 4.2.4 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Counseling
    • 4.3.2 Laboratory Services
    • 4.3.3 Data Interpretation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Microarray
    • 4.4.4 Fluorescence In Situ Hybridization
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Chromosomal Abnormalities
    • 4.5.2 Genetic Disorders
    • 4.5.3 Metabolic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Centers
    • 4.6.4 Specialty Clinics
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Sample Collection
    • 4.7.2 DNA Isolation
    • 4.7.3 Sequencing
    • 4.7.4 Data Analysis
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Invasive
    • 4.8.2 Non-invasive
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preconception
    • 4.9.2 Prenatal
    • 4.9.3 Postnatal

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Natera
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Invitae
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Myriad Genetics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Progenity
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Genetic Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Perkin Elmer
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Veritas Genetics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ariosa Diagnostics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Billion To One
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sema4
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Color Genomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genomic Prediction
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Fulgent Genetics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Good Start Genetics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Counsyl
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gene Dx
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Cooper Genomics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Aperiomics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Juno Diagnostics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Predictive Laboratories
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us